Investment Thesis
Galectin Therapeutics is technically insolvent with stockholders' equity of -$132M, liabilities of $146M against only $15.8M in assets. The company generates no revenue, burns $3.9M in cash annually, and faces critical liquidity risk as its $14.1M cash position will be depleted within 3-4 years at current burn rates without major financing or revenue generation.
Strengths
- Current ratio of 2.15x provides minimal short-term liquidity cushion
- Slight improvement in net losses YoY (-0.4% change) and EPS improvement (+36.8%) suggests modest cost containment
- Pharmaceutical sector exposure provides potential for transformative product development
Risks
- Negative stockholders' equity of -$132M indicates technical insolvency with liabilities exceeding assets by 9.2x
- Zero revenue indicates no commercial products; pre-clinical/development stage company with no near-term income visibility
- Negative operating cash flow of -$3.9M with only $14.1M cash reserves; company faces existential funding risk within 3-4 years
- Massive debt burden ($146M) relative to asset base with no cash generation capability
- Imminent dilution risk requiring significant equity raises to avoid bankruptcy
Key Metrics to Watch
- Cash balance depletion rate and runway to capital raise urgency
- Progress toward clinical trial milestones or regulatory approvals for pipeline drugs
- Debt restructuring announcements or covenant violations
- Revenue generation timeline and product development advancement
Financial Metrics
Revenue
N/A
Net Income
-5.0M
EPS (Diluted)
$-0.08
Free Cash Flow
-3.9M
Total Assets
15.8M
Cash
14.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-32.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.15x
Quick Ratio
2.15x
Debt/Equity
N/A
Debt/Assets
926.4%
Interest Coverage
-3.88x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:19:18.317681 |
Data as of: 2026-03-31 |
Powered by Claude AI